{
    "clinical_study": {
        "@rank": "30256", 
        "arm_group": [
            {
                "arm_group_label": "Omega-3 fatty acid capsules", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "corn oil", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether omega-3 fatty acids supplementation are\n      effective in the improvement of suboptimal health status and cardiovascular risk."
        }, 
        "brief_title": "Fish Oil and Cardiovascular Suboptimal Health", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Suboptimal Health Status", 
        "detailed_description": {
            "textblock": "The Suboptimal health status questionnaire (SHSQ-25) is used to evaluate the suboptimal\n      health status. The SHSQ-25 includes 25 questions. The score of the SHSQ-25 is from 0 to 100.\n      Suboptimal health status is defined as the SHSQ-25 score above than 35. The higher scores of\n      the SHSQ-25 one gets, the more severity of suboptimal health status he/she has. All\n      participants are asked to fill in the SHSQ-25 before and after the intervention. If the\n      score decreases after the intervention, it means that the suboptimal health status has been\n      improved."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. suboptimal health status, defined as the score of suboptimal health questionnaire\n             \u226535.\n\n          2. at least one of cardiovascular risk factors:\n\n               -  overweight or obesity, defined as body mass index (BMI) \u226524 kg/m2.\n\n               -  systolic blood pressure \u2265120 and <140 mmHg or diastolic blood pressure \u226580 and\n                  <90 mmHg.\n\n               -  fasting plasma glucose \u2265100 and <126 mg/dL\n\n               -  total cholesterol \u2265200 and <240 mg/dL, triglyceride \u2265150 and <200 mg/dL, low\n                  density lipoprotein-cholesterol \u2265130 and <160 mg/dL,and/or high density\n                  lipoprotein-cholesterol <40 mg/dL\n\n          3. written informed consent\n\n        Exclusion Criteria:\n\n          1. history of system diseases, such as cardiovascular diseases, digestive system\n             diseases, diseases of respiratory system, blood and immune system diseases, nervous\n             system diseases, endocrine system diseases, and diseases of the genitourinary system.\n\n          2. history of mental illness.\n\n          3. pregnant or breastfeeding.\n\n          4. use of antihypertensive, antidiabetic, or lipid-lowering drugs within the past two\n             weeks.\n\n          5. use of fish oil capsules or other supplements containing omega-3 fatty acids within\n             the past two weeks.\n\n          6. allergy or intolerance to fish oil, corn oil, omega-3 fatty acids, or vitamin E.\n\n          7. participation in another trial.\n\n          8. unable to promise to not use drugs and other fish oils during the study.\n\n          9. unable to provide informed written consent."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103517", 
            "org_study_id": "2012BAI37B04", 
            "secondary_id": "N3FACSH"
        }, 
        "intervention": [
            {
                "arm_group_label": "Omega-3 fatty acid capsules", 
                "description": "Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.", 
                "intervention_name": "Omega -3 fatty acids", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "corn oil", 
                "description": "Each subject assigned to the control group will receive 4 g/day capsule of corn oil.", 
                "intervention_name": "Placebo: Corn oil", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 1, 2014", 
        "location": [
            {
                "contact": {
                    "email": "dsynh@126.com", 
                    "last_name": "Sheng-Yong Dong, M.D.", 
                    "phone": "+86-15810093631"
                }, 
                "facility": {
                    "address": {
                        "city": "Beijing", 
                        "country": "China", 
                        "state": "Beijing", 
                        "zip": "100853"
                    }, 
                    "name": "Chinese PLA General Hospital"
                }, 
                "investigator": {
                    "last_name": "Sheng-Yong Dong, Ph.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Jun Fu, M.D", 
                    "phone": "86-138-4509-1380"
                }, 
                "facility": {
                    "address": {
                        "city": "Harbin", 
                        "country": "China", 
                        "state": "Heilongjiang", 
                        "zip": "150001"
                    }, 
                    "name": "First Affiliated Hospital of Harbin Medical University"
                }, 
                "investigator": {
                    "last_name": "Jun Fu, M.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Ping Shuai, M.D.", 
                    "phone": "+86-13438087662"
                }, 
                "facility": {
                    "address": {
                        "city": "Chengdu", 
                        "country": "China", 
                        "state": "Sichuan", 
                        "zip": "610000"
                    }, 
                    "name": "Sichuan Province People's Hospital"
                }, 
                "investigator": {
                    "last_name": "Yu-Ping Liu, M.D", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Risk and Prevention Study: Optimisation of the Preventive Strategies and Evaluation of the Efficacy of n-3 Fatty Acids in Subjects at High Cardiovascular Risk and Suboptimal Health Status", 
        "overall_contact": {
            "email": "zq301@126.com", 
            "last_name": "Qiang Zeng, M.D., Ph.D", 
            "phone": "+86-10-68295751"
        }, 
        "overall_contact_backup": {
            "email": "dsynh@126.com", 
            "last_name": "Sheng-Yong Dong, M.D., Ph.D", 
            "phone": "+88-15810093631"
        }, 
        "overall_official": [
            {
                "affiliation": "Chinese PLA General Hospital", 
                "last_name": "Qiang Zeng, M.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Chinese PLA General Hospital", 
                "last_name": "Sheng-Yong Dong, M.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Science and Technology", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The improvement of suboptimal health status is evaluated  by the change of the SHSQ-25 scores after intervention.", 
                "measure": "the improvement of suboptimal health status", 
                "safety_issue": "No", 
                "time_frame": "three months"
            }, 
            {
                "description": "To investigate the changes of traditional cardiovascular risk factors such as blood pressure, lipids, fasting plasma glucose, and body mass index with three months supplementation of omega-3 fatty acids. Abnormal cardiovascular risk factors are defined according to the Adult Treatment Panel III criteria for metabolic syndromes and the recommendation by the Working Group on Obesity in China. The number of abnormal cardiovascular risk factors for each participant is recorded before and after intervention. If the number decreases after intervention, it means that the traditional cardiovascular risk factors have been improved.", 
                "measure": "the improvement of traditional cardiovascular risk factors", 
                "safety_issue": "No", 
                "time_frame": "three months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103517"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Chinese PLA General Hospital", 
            "investigator_full_name": "Qiang Zeng, MD", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Chinese PLA General Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chinese PLA General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}